AU2001261529A1 - Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function - Google Patents

Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function

Info

Publication number
AU2001261529A1
AU2001261529A1 AU2001261529A AU6152901A AU2001261529A1 AU 2001261529 A1 AU2001261529 A1 AU 2001261529A1 AU 2001261529 A AU2001261529 A AU 2001261529A AU 6152901 A AU6152901 A AU 6152901A AU 2001261529 A1 AU2001261529 A1 AU 2001261529A1
Authority
AU
Australia
Prior art keywords
pttg
lymphocytes
targeting
expression
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261529A
Inventor
Gregory A. Horwitz
Shlomo Melmed
Rostyslav Stoika
Xun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/569,956 external-priority patent/US6894031B1/en
Priority claimed from US09/730,469 external-priority patent/US20030018001A1/en
Priority claimed from US09/777,422 external-priority patent/US20020147162A1/en
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2001261529A1 publication Critical patent/AU2001261529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001261529A 2000-05-12 2001-05-12 Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function Abandoned AU2001261529A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US09/569,956 US6894031B1 (en) 1996-11-21 2000-05-12 Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US09569956 2000-05-12
US68791100A 2000-10-13 2000-10-13
US09687911 2000-10-13
US09730469 2000-12-04
US09/730,469 US20030018001A1 (en) 1996-11-21 2000-12-04 Methods of using pituitary tumor transforming gene (PTTG) carboxy-terminal peptides to inhibit neoplastic cellular proliferation and/or transformation of breast and ovarian cells
US09/777,422 US20020147162A1 (en) 1996-11-21 2001-02-05 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (PTTG)
US09777422 2001-02-05
US09/854,326 US6913926B2 (en) 1996-11-21 2001-05-11 Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
US09854326 2001-05-11
PCT/US2001/015438 WO2001088116A2 (en) 2000-05-12 2001-05-12 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods

Publications (1)

Publication Number Publication Date
AU2001261529A1 true AU2001261529A1 (en) 2001-11-26

Family

ID=27541918

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001261528A Abandoned AU2001261528A1 (en) 2000-05-12 2001-05-12 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
AU2001261529A Abandoned AU2001261529A1 (en) 2000-05-12 2001-05-12 Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001261528A Abandoned AU2001261528A1 (en) 2000-05-12 2001-05-12 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)

Country Status (5)

Country Link
US (1) US6913926B2 (en)
EP (3) EP1280907A2 (en)
JP (2) JP2003533988A (en)
AU (2) AU2001261528A1 (en)
WO (3) WO2001087039A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20060047414A1 (en) * 2004-09-02 2006-03-02 Matsushita Electric Industrial Co., Ltd. Probe-car system using beacon and apparatus therefore
KR100627377B1 (en) 2005-03-04 2006-09-25 한국생명공학연구원 - 1 Small Interfering RNA Specific for PTTG1 Expression Vector thereof and Therapeutic Agent for Tumor Comprising the Same
DE112012001456T5 (en) 2011-04-19 2013-12-19 Cummins Inc. A system, method and apparatus for treating a platinum-contaminated catalytic component
AU2018395010B2 (en) * 2017-12-29 2022-07-28 Genemedicine Co., Ltd. Cell sheet for gene delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009442A1 (en) 1989-02-08 1990-08-23 Uab Research Foundation Antiproliferation factor
AU4535893A (en) 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
WO1995025809A1 (en) 1994-03-23 1995-09-28 Ohio University Compacted nucleic acids and their delivery to cells
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
JPH07322892A (en) 1994-05-30 1995-12-12 Tonen Corp Method for screening immunosuppressive substance
JPH09173053A (en) 1995-12-27 1997-07-08 Tonen Corp Yeast variant highly sensitive to immunosuppressive agents and its application
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
ATE321854T1 (en) 1996-11-21 2006-04-15 Cedars Sinai Medical Center HYPOPHYSTIC TUMOR CAUSING GENES AND RELATED PRODUCTS
AU750565B2 (en) 1997-03-03 2002-07-25 Duke University Immunosuppression

Also Published As

Publication number Publication date
WO2001088116A9 (en) 2002-06-06
WO2001087935A3 (en) 2002-08-08
EP1280906A2 (en) 2003-02-05
JP2003533988A (en) 2003-11-18
JP2004526404A (en) 2004-09-02
WO2001087935A2 (en) 2001-11-22
EP1280908A2 (en) 2003-02-05
EP1280907A2 (en) 2003-02-05
WO2001088116A3 (en) 2002-05-10
WO2001087935A9 (en) 2002-12-27
WO2001087039A3 (en) 2002-03-21
WO2001088116A2 (en) 2001-11-22
WO2001087039A2 (en) 2001-11-22
AU2001261528A1 (en) 2001-11-26
US20030186902A1 (en) 2003-10-02
US6913926B2 (en) 2005-07-05

Similar Documents

Publication Publication Date Title
AU1220799A (en) Controlled synthesis and metal-filling of aligned carbon nanotubes
AU5055199A (en) Hydrophobic modification of chargeable pigment particles
AU6475098A (en) Controlling development of an oil or gas reservoir
AU5273398A (en) Atomizer
AU8169498A (en) Backpack assembly and method of use
AU1124499A (en) Human papillomavirus vectors
AU8593398A (en) Zinc-based electrode particle form
AU5184198A (en) Soft aspiration tip
AU4551599A (en) Novel therapeutic agents that modulate endothelin receptors
AU6681198A (en) Abrasion-resistant ink compositions and methods of use
AU1242399A (en) Nose sprayer
AUPP019997A0 (en) Dump body
AU7497798A (en) 3-epi compounds of vitamin d3 and uses thereof
AU7175598A (en) Aqueous dispersions of polyamides
HUP9800574A3 (en) Promoter of the cdc 25b gene, its preparation and use
AU2091799A (en) Uses of alpha-conotoxin peptides
AU9526498A (en) Acoustic landmine prodding instrument with force feedback
AU7729498A (en) Methods and uses for transposon-based gene targeting
AU2001261529A1 (en) Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function
AU2001259676A1 (en) Nanosized particles of molybdenum sulfide and derivatives and uses thereof
AU3208099A (en) Modification of metallic particles
AU1995699A (en) Slot jet reattachment nozzle and method of operation
AU2413299A (en) Novel vitamin d3 amide derivatives
AU9131698A (en) Human genes regulated by human cytomegalovirus and interferon
AU7968098A (en) Transformation of wheat with the cyanamide hydratase gene